Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (341-350 of 441) with videos related to

Pageof 45
Sort By:
Human Vaccines & Immunotherapeutics|August 3, 2019
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trialFabien Zoulim, Claire Fournier, François Habersetzer, et al.
Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.
Antiviral Therapy|March 27, 2009
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatmentAndreas Erhardt, Katja Deterding, Yves Benhamou, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Frontiers in Genetics|November 22, 2019
Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation SequencingFrédégonde About, Stéphanie Bibert, Emmanuelle Jouanguy, et al.
Joint Bone Spine|July 9, 2010
Tocilizumab: therapy and safety managementThao Pham, Pascal Claudepierre, Arnaud Constantin, et al.
JHEP Reports : Innovation in Hepatology|December 11, 2023
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitorsLucia Parlati, Mehdi Sakka, Aurelia Retbi, et al.
Clinics and Research in Hepatology and Gastroenterology|April 11, 2022
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic responseJessica Azzi, Céline Dorival, Carole Cagnot, et al.
The New England Journal of Medicine|March 21, 2014
Ribavirin for chronic hepatitis E virus infection in transplant recipientsNassim Kamar, Jacques Izopet, Simona Tripon, et al.
Annals of Internal Medicine|December 11, 2023
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice GuidelineAhmed Arslan Yousuf Awan, Marina C Berenguer, Annette Bruchfeld, et al.
Pageof 45

Showing results (341-350 of 441) with videos related to

Sort By:
Pageof 45
Human Vaccines & Immunotherapeutics|August 3, 2019
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trialFabien Zoulim, Claire Fournier, François Habersetzer, et al.
Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.
Antiviral Therapy|March 27, 2009
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatmentAndreas Erhardt, Katja Deterding, Yves Benhamou, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Frontiers in Genetics|November 22, 2019
Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation SequencingFrédégonde About, Stéphanie Bibert, Emmanuelle Jouanguy, et al.
Joint Bone Spine|July 9, 2010
Tocilizumab: therapy and safety managementThao Pham, Pascal Claudepierre, Arnaud Constantin, et al.
JHEP Reports : Innovation in Hepatology|December 11, 2023
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitorsLucia Parlati, Mehdi Sakka, Aurelia Retbi, et al.
Clinics and Research in Hepatology and Gastroenterology|April 11, 2022
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic responseJessica Azzi, Céline Dorival, Carole Cagnot, et al.
The New England Journal of Medicine|March 21, 2014
Ribavirin for chronic hepatitis E virus infection in transplant recipientsNassim Kamar, Jacques Izopet, Simona Tripon, et al.
Annals of Internal Medicine|December 11, 2023
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice GuidelineAhmed Arslan Yousuf Awan, Marina C Berenguer, Annette Bruchfeld, et al.
Pageof 45